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Abstract
Previously, we determined the incidence of dual infections in a South African cohort and its association with
higher viral setpoint. Ten years later, we compare the incidence and impact of dual infections at transmission on
viral setpoint in a geographically similar cohort (n¼ 46) making use of both the heteroduplex mobility assay
(HMA) and the more recent single genome amplification (SGA) approach. HIV incidence was lower in this
cohort (7% compared to 18%), and we find a similar reduction in the number of dual infections (9% compared to
19%). Unlike the previous study, there was no association between either dual infection (n¼ 4) or multivariant
transmission (n¼ 7) and disease progression. This study emphasized the importance of monitoring changes in
the HIV epidemic as it may have important ramifications on our understanding of the natural history of disease.
Introduction
As the HIV epidemic evolves, the contribution of factorsthat increase viral load and disease progression, such
as HIV-1 dual infection,1,2 may change. The incidence of
dual infections, defined as infection with two epidemio-
logically unlinked HIV variants, could influence the disease
profile in populations and therefore public health planning.
In a previous study we determined that the incidence of
subtype C dual infections in a cohort of female sex workers
recruited from 1996 to 1999 in KwaZulu-Natal, South Africa
was 19%.1 Ten years after the first analysis, this study aims
to determine the incidence of dual infections in the more
recent CAPRISA 002 cohort in KwaZulu-Natal, and the role
of dual infections in rapid disease progression in this co-
hort.3 Similar to the initial study, we used the heteroduplex
mobility assay (HMA) together with sequencing to identify
dual infections. HMA can detect variants present as low as
1%; however, it is limited in that it cannot differentiate very
closely related viruses.1 We thus verified this approach on a
subset of samples using single genome amplification (SGA)
followed by sequencing. The SGA approach has become the
standard method for defining the transmission bottleneck
as it can reliably detect transmission of closely related
viruses, although it will only be 95% confident of detecting
variants present at a frequency greater than 15% when
sampling at least 20 sequences.4
It is well established that there is an extreme virus popu-
lation bottleneck following transmission,5–7 with an estimated
80% of infections being a result of transmission of a single
virus or virus-infected cell. The remaining 20% are infected
with multiple variants (quasispecies) where more than one
virus, transmitted from the donor, results in productive clin-
ical infection. Like dual infection, multiple variant transmis-
sion has been associated with rapid disease progression.5
Factors that have been shown to affect susceptibility to HIV
infection8 also appear to increase the chance of multiple var-
iant transmission: studies in Kenya, Rwanda, and Zambia
have shown that women with sexually transmitted infections
(STIs) or on hormonal contraceptives were more likely to
harbor diverse viral populations following transmission.9,10
Furthermore, a study in Tanzania showed that frequency of
infection with a diverse viral population was higher in high-
risk women compared to women with lower-risk behavior.11
In this study we characterized the frequency of dual in-
fection and multiple variant transmission in 46 individuals of
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whom 12 (26%) were identified as rapid disease progressors
based on CD4þ cell counts less than 350 ml/ml within the first
year of infection.12 We also investigated the role/impact that
STIs might have in multiple variant transmissions and disease
progression.
Materials and Methods
Plasma samples were obtained within 3 months of infection
from the CAPRISA 002 acute infection cohort, Durban, South
Africa.3 Genital samples were collected every 6 months and
tested for sexually transmitted infections [Chlamydia tracho-
matis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomo-
nas vaginalis, Bacterial vaginosis, syphilis, and herpes simplex
virus type 2 (HSV-2)] as previously described.13
Viral RNA was reverse transcribed using the Superscript III
Reverse Transcriptase (Invitrogen) with either Env-N (nt
9171–9145) or ED33 (nt 7380–7361) primers (primer number-
ing according to HXB2). Population polymerase chain reac-
tion (PCR) was carried out with a median input of 105 copies
of viral RNA as determined using the plasma viral load
measurement, with two participants where only two RNA
copies were supplied. The Env C2–C3 510-bp region was
amplified using nested PCR.1 Minor viral populations
infecting CAP37 were identified using two antisense strain-
specific primers: 37-R2 (nt 9053–9033) and 37-R1 (nt 8870–
8847). Env sequences obtained using SGA were acquired from
GenBank (FJ443128 to FJ444632).7
HMA was performed as described.14 PCR products (510
bp) were cloned using the pGEM-T-Easy TA cloning kit
(Promega) and sequenced using ABI PRISM dye terminator
cycle-sequencing kit V3.1 (Applied Biosysytems). Sequences
were aligned using Clustal W and DNA distances were esti-
mated using the Kimura two-parameter model (Mega, ver-
sion 3.1; Molecular Evolution Genetic Analysis).
Comparison of the association of STI coinfection between
individuals infected with multiple and single variants was
performed using the two-tailed Fishers exact test, and com-
parison of median viral load setpoint and CD4þ cell counts
was performed using the Mann–Whitney t-test, GraphPad
Prism (version 4; GraphPad Software).
Results
This study compares the incidence and impact of dual in-
fection on disease progression in two cohorts of high-risk
women from KwaZulu-Natal, South Africa. The previous
study (Du Cohort) recruited 31 women between 1996 and
1999,1 whereas the current study (CAPRISA 002 cohort)
characterizes recent infection in 46 women recruited between
2004 and 2009.3 The HIV incidence in the Du cohort was 18%
compared to 7% in the CAPRISA 002 cohort (Table 1),3,15 with
participants in the Du cohort having a higher number of
sexual partners (median¼ 20 clients/week, range of 5–40)16
compared to those in the CAPRISA cohort (median¼ 2
clients/week; range of 0–30).3
Most early studies have used the HMA to screen for di-
versity following transmission,1,2,6 however, more recently
the SGA and sequencing approach was shown to be more
accurate as it controls for both resampling and recombination
during amplification, both of which can confound the inter-
pretation of the results.7,8 To assess the reliability of the C2–C3
region HMA to detect multiple variants, we compared the
DNA distance between complete env SGA sequences to those
of the C2–C3 regions alone. We found that the maximum
DNA distance of env of the multiple variants infecting 14 in-
dividuals identified by Abrahams et al.7 ranged from 0.73 to
8.49%7 and for the C2–C3 region ranged from 1.04 to 10.57%.
Only sequences from a fifteenth participant, classified by env
SGA sequencing as infected with multiple but very closely
related variants, had no changes in C2–C3. As it was previ-
ously shown that a single band was visible on an HMA gel
when DNA distance was< 0.86%,1 we hypothesized that
HMA should be able to identify the majority of multivariant
infections. We then directly compared the SGA and HMA ap-
proaches on samples from a further 19 individuals. We found
concordant results for 17/19 participants of which 13 were
classified as homogeneous and the remaining 6 as heteroge-
neous infections. Of the two discordant samples (CAP84 and
CAP221) (Fig. 1A and B), SGA classified these as homogeneous
whereas they were classified as heterogeneous by HMA.
CAP84 was studied using SGA at the 2 wpi visit whereas HMA
demonstrated heteroduplex banding patterns 2 weeks later (4
wpi); thus it is possible that CAP84 either became infected with
a second variant between sampling or fluctuations in the viral
population occurred so that the second variant became more
dominant over time. For CAP221, 58 clones were tested by
HMA whereas the SGA approach sequenced only 21 amplicons
so it is possible that the minor variants were missed due to
limited sampling (Fig. 1C). It has previously been shown that
by sequencing only 20 env sequences, there is only a 95% con-
fidence interval of detecting variants that occur at 15% or
greater frequency within the virus population.8
As HMA reliably identified viral variants with high diver-
sity, we screened 39 individuals for genetic complexity fol-
lowing transmission using HMA. Nine of 39 individuals (23%)
were classified as multivariant transmissions based on unique
banding patterns and high diversity (maximum C2–C3 DNA
distance 0.8–16.9%). Of these nine, five participants were in-
fected with variants forming a single phylogenetic cluster,
while three participants harbored viruses with sequences that
separated into distinct phylogenetic lineages, confirming that
these individuals were dually infected (Fig. 1D). The ninth in-
dividual, CAP37, was classified as a potential dual infection
using the SGA approach7 and was confirmed in this study
using strain-specific PCR (Fig. 1D). By combining the 39 par-
ticipants screened by HMA and 7 participants obtained from
Abrahams et al.,7 11/46 individuals were shown to be infected
with multiple variants with 4/11 individuals demonstrated to
be infected with phylogenetically distinct strains (Fig. 1D).
To define factors that could predispose individuals to
infection with diverse virus populations we determined
whether multiple variant infection was associated with con-
current STIs (Table 1). Bacterial vaginosis was excluded from
the analysis due to its high incidence (34/46; 74%) within the
cohort. Although nearly 50% (22/46) of the cohort was in-
fected with one or more STIs, we found more women infected
with multivariants having concomitant STIs (8/11; 73%) than
women with single variant transmissions (14/35; 40%) ( p¼
0.0848) (Table 1).
When we compared CD4 cell counts at 12 months postin-
fection between those infected with single (n¼ 34) vs. multi-
ple variants (n¼ 10) (Table 1), the median values (422 cells/ml;
range¼ 241–1030 and 374 cells/ml; range¼ 188–695, respec-
tively) did not differ significantly between the two groups
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( p¼ 0.2567). Similarly, the median viral load of indi-
viduals infected with single variants (23,900 copies/ml;
range¼ 400–1,680,000) was not significantly lower ( p¼
0.7902) than those infected with multiple variants (47,650
copies/ml; range¼ 400–1,230,000). In this cohort 12 of the 46
individuals were classified as rapid progressors based on
CD4þ counts below 350 cells/ml within the first year of in-
fection and 6 were identified as controllers with viral loads
below 2000 RNA copies/ml.12 Of the rapid progressors only
two individuals were dual infected and a further three were
infected with multiple variants at transmission. Although, the
median CD4þ cell count (345 cells/ml; range¼ 274-479 cells/
ml) of the four dual-infected individuals was lower than those
individuals infected with single variants (422 cells/ul; range
241–1030 cells/ml), this association was not significant ( p¼
0.1908). Thus, despite several independent studies demon-
strating an association between dual infection and disease
progression, including the study of the Du cohort, this factor
does not appear to be a major factor accounting for the high
number of rapid disease progressors in this cohort.1,2,5
Discussion
Characterization of transmitted viruses and factors that
affect the transmission bottleneck are important for both
vaccine studies and to understand HIV pathogenesis. This
Table 1. Clinical and Virological Characteristics of Individuals from the Du and Caprisa Cohorts
Description of the cohort







Total number 31 46 35 11
Mean age years (range) 25 (17–41) 27.9 (18–59) 29.2 (18–59) 23.2 (18–39)
Median time (weeks) of
infectionb (range)
5.2 (1–22) 5 (2–12) 5 (2–12) 5 (2–9)
Median viral load at
12 months postinfectionc
(copies/ml) (range)
5404 (50–321,040) 29,450 (400–1,680,000) 23,900 (400–1,680,000) 47,650 (400–1,230,000)
Median CD4þ counts at
12 months postinfectionc
(cells/ml) (range)
N/A 411 (188–1030) 422 (241–1030) 374 (188–695)
HIV prevalence (%) 56 59.6
HIV incidence (%) 18 7
Dual infection incidence 19 9
Sexually transmitted infection (STI)
Any STI (including BV)d N/A 41/46 (89%) 31/35 (89%) 10/11 (91%)
Any STI (excluding BV)d N/A 22/46 (47.8%) 14/35 (40%) 8/11 (73%)




















CAP37 6 N. gonorrhoea 212 11.6 104,000 274 Y
CAP69 5 N. gonorrhoea 111 1.3 1,230,000 202 N
CAP84 3 C. trachomatis 49 15.2 4,350 479 Y
CAP136 2 No N/A 1.4 400 695 N
CAP137 7 N. gonorrhoea 94 16.9 265,000 338 Y
CAP221f 2 N. gonorrhoea 58 0.8 53,100 468 N
CAP222 6 T. vaginalis 102 5.2 448 654 N
CAP224 5 No 38 1.3 360,000 346 N
CAP260g 2 M. genitalium N/A 3.8 N/A N/A N
CAP261 9 HSV-2 86 5.2 42,200 396 N
CAP267 5 No 166 7.7 4,420 352 Y
aData obtained from Grobler et al.1 and Ramjee et al.16
bInfection date was estimated to be the mid-point between the last HIV-negative test and first HIV-seropositive test, or 14 days where
individuals were HIV PCR positive, antibody negative.
cViral load and CD4 count analysis was performed on 44 women as two rapid progressors, one infected with a single variant and one
infected with multiple variants, were referred for antiretroviral treatment before 12 months.
dBacterial vaginosis (BV) occurred in 74% of women (34/46) and the analysis was performed both including and excluding BV.
eDNA distance between clonal C2–C3 env sequences except CAP136 and CAP260 where the DNA distance is derived from the C2–C3 region
of env single genome amplification (SGA) sequences.7
fCAP221 sampling occurred prior to seroconversion.
gCAP260 died before 12 months postinfection.
N/A, not available for comparison.
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FIG. 1. The heteroduplex mobility assay (HMA) identified multiple variant infection. (A) Representative HMA gels of CAP84 (i)
and CAP221 (ii) showing the 510-bp C2–C3 clonal amplicons (clone number prefixed with c) mixed with a reference clone. In some
lanes, two clones were mixed with the reference clone. Only representative clones of unique banding patterns were sequenced and
these are labeled, whereas lanes showing amplicons that were not sequenced are marked with an asterisk. The 1-kb molecular
weight marker was used in lane M (Promega). (B) Neighbor-joining trees of CAP84 (i) and CAP221 (ii) showing the phylogenetic
relationship between the respective clonal C2–C3 sequences. (C) Comparison between the C2–C3 clonal sequences and the SGA
derived sequences (indicated by a black dot) of CAP84 (i) and CAP221 (ii) aligned to the consensus of the SGA sequences using
Highlighter (www.hiv.lanl.gov). (D) Neighbor-joining tree of the C2–C3 region of all 46 participants and reference subtype C
(www.hiv.lanl.gov) with replicates of 500 and bootstrap values> 70 indicated. The sequences of CAPRISA participants infected
with homogeneous variants are shown by either black squares (HMA identified clones) or black circles [C2–C3 region identified by
single genome amplification (SGA)] and the participants infected with diverse strains are indicated by participant ID. To clearly
illustrate infection with diverse strains, the two sequences with the highest maximum DNA distance from each participant with
multivariant infection are shown. For two participants (CAP137 and CAP37) sequences from two time points are illustrated (wpi,
weeks postinfection). For CAP37, strain-specific primers were designed to the gp41 region of a recombinant identified by SGA at 2
wpi and used to selectively amplify the second strain at 7 wpi. Color images available online at www.liebertonline.com/aid
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study utilized HMA together with sequencing, as well as
previously published SGA-derived sequences to further elu-
cidate the relationship between Env viral diversity at trans-
mission and disease progression. We also compared this data
to a study completed 10 years earlier to identify possible
changes in trends over time that may be driving the high
number of rapid disease progressors in this cohort. Changes
in the HIV epidemic have important ramifications on our
understanding of the natural history of disease and our design
of preventive measures such as vaccines.
This study shows that HMA based on the Env C2–C3 re-
gion, followed by cloning and sequencing, can reliably detect
most multivariant transmission events when compared to the
more stringent SGA sequencing method.4,7,8 Although the
SGA approach provides the numeration of transmitted vari-
ants and in-depth sequence information, there are practical
limitations on the number of sequences analyzed and there-
fore it may underestimate multiple variant transmission due
to limited sampling. Although HMA may not detect closely
related variants, the advantage of screening numerous clones
enables the detection of variants present at low frequency. The
HMA approach also requires sufficient input template to
sample all quasispecies present14 and may thus underestimate
diversity in individuals with low viral loads. Taken together,
both SGA and HMA approaches are likely to provide only a
minimum estimation of frequency of dual infection and
multivariant transmission.
The earlier study identified 19% (6/31) of participants with
dual infection following transmission by HMA, cloning, and
sequencing.1 Using both HMA and SGA, the current study
detected only 9% of individuals dually infected with phylo-
genetically distinct viruses following infection. A further 15%
of the women were infected with multiple variants (quasis-
pecies). Thus a total of 24% of participants were infected with
variants of high diversity, in concordance with other stud-
ies.7,8 This study also provides further evidence that diagnosis
of STIs at enrollment may be associated with disruption of the
genetic bottleneck, suggesting that the mucosal barrier plays a
role in restricting transmission. Although this association was
not statistically significant there was a trend toward associa-
tion as 73% of individuals infected with multiple variants
were diagnosed as carrying one or more STIs compared to
only 40% with single variant infection. This result is most
likely due to the high incidence of different STIs in the cohort
with only some associated with increased susceptibility to
HIV infection.17
Our study identified 9% dual infections compared to 19% in
the Du cohort study 10 years earlier1 from the same geographic
region. The frequency of dual infection has been associated
with risk behavior11 and this reduction in frequency is in line
with the difference in HIV incidence between the two cohorts
(the incidence in the CAPRISA cohort was 7%3 compared to
18% in the Du cohort1) as well as differences in risk behavior.
Recently, dual infections were not identified in a chronic
infection cohort from the same region,18 and this is most likely
due to the differences between the cohorts such as stage of
disease and exposure to antiretroviral (ARV) therapy. This
highlights the complexity of intercohort comparisons whereby
changes in cohort characteristics can impact disease outcomes.
In conclusion, previously, an association between dual in-
fection and disease progression was found in the Du cohort
using the same experimental approach.1,2 However, here we
find in the CAPRISA 002 cohort that rapid disease progres-
sion was neither significantly associated with dual infection
nor infection with multiple variants. It is not clear why indi-
viduals with dual infections are not rapid progressors, how-
ever, virological characteristics are only one of the factors
affecting disease progression that is influenced by complex
interactions between host genetics, immunological responses,
and coinfections. The two cohorts were recruited from similar
populations with similar HLA profiles and it is therefore
unlikely that host genetics would account for the different
results in these studies. Previous studies on the CAPRISA 002
cohort have shown that neither HIV-1-specific interferon
gamma (IFN-g) responses in acute infection19 nor develop-
ment of autologous neutralizing antibody responses20 appear
to impact disease progression. Thus far, studies on the same
cohort have shown that viral control is associated with HLA-
B*5801 CTL escape mutations21 and the development of a
subset of CD8þ memory cells.22 However, higher viral loads
and maintenance of CD4þ cells in the CAPRISA 002 cohort are
associated with elevated inflammation in the genital track13
and increased levels of specific cytokines in the plasma during
acute infection.23 We have yet to determine the major factor
driving the high rates of disease progression observed in this
cohort.
Accession Numbers
Env sequences were acquired from GenBank: FJ443128 to
FJ444632.
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